"MEDEZE Group” in High Demand: IPO Fully Subscribed with 268 Million Shares Reaffirms Leadership in the Industry with Strong Financial Fundamentals. Fundraising to Expand Profit Base Amid Business Growth Cycle. IPO Price Set at 9 Baht, Offering Attractive Upside. Ready to Begin Trading on October 15, 2024.

Mr. Payuphat Mahaphol, Managing Director of Investment Banking at Yuanta Securities (Thailand) Co., Ltd., acting as the financial advisor and underwriter for Medeze Group Public Company Limited (MEDEZE), announced that the company’s IPO has received overwhelming interest from investors nationwide. All 268 million shares offered were fully subscribed at the set price of 9 THB per share, which strongly reflects investor confidence in MEDEZE’s leadership in the industry, robust financial foundation, and the positive cycle in the sector. The company’s strategic growth plans and profit expansion opportunities further reinforce this confidence. MEDEZE is fully prepared to commence trading on the Stock Exchange of Thailand (SET) on its first trading day, October 15, 2024. The company expects continued positive reception from investors moving forward.

Currently, MEDEZE has a registered and fully paid-up capital of 400 million THB, equivalent to 800 million shares. These shares will be listed as common stock on the Stock Exchange of Thailand (SET). This initial public offering (IPO) involves the issuance of up to 268 million new common shares with a par value of 0.50 THB per share, representing no more than 25.09% of the total issued and fully paid-up common shares after this capital increase. MEDEZE will be categorized under the Services (SERVICE) sector in the Healthcare (HEALTH) industry on the SET.

Dr. Veerapol Khemarangsan, Chief Executive Officer of Medeze Group Public Company Limited (MEDEZE), stated that the company specializes in the analysis, isolation, cultivation, and storage of stem cells, as well as the assessment of immune cell potential (NK Cells). With over 14 years of continuous business experience, MEDEZE provides long-term stem cell storage services utilizing cutting-edge innovations and technology. The company operates through five subsidiaries:

1. Medeze NK Co., Ltd. - Focuses on providing immune cell potential testing services (NK Cells).
2. Medeze Cosmeceutical Co., Ltd. - Engages in the sale of beauty products under the brand "DAA" and dietary supplements.
3. Medeze Research and Development Co., Ltd. - Conducts experimental research and development in biotechnology.
4. Medeze Treasury Pte. Ltd. - Operates as an investment company, managing and overseeing the trademarks of the group.
5. Medeze Group Pte. Ltd. - Engages in experimental research and development in biotechnology.

The company possesses significant capabilities in its services, utilizing a total of 38 liquid nitrogen tanks. It has a maximum capacity for processing 2,880 blood cases per year, 4,560 tissue cases per year, and conducting NK cell potential tests for up to 1,920 cases per year. The company has partnerships with 228 hospitals across Thailand and has distributors both domestically and internationally, including Vietnam, Singapore, Myanmar, Indonesia, and Cambodia.

Additionally, the company employs numerous leading scientists and professionals in the biotechnology field, strengthening its network with top-tier medical institutions. It also operates a state-of-the-art cleanroom facility classified as Class 100, equipped with advanced tools and technologies in stem cell banking. These include liquid nitrogen storage systems, the AutoXpress automated hematopoietic stem cell separator, and the Quantum automated mesenchymal stem cell expansion system.

The company has earned international trust through its adherence to global standards for frozen storage, certified by the Association for the Advancement of Blood and Biotherapies (AABB) from the United States. The AABB is an organization that rigorously accredits stem cell banking operations, following international quality system standards as specified by the U.S. Food and Drug Administration (U.S. FDA). These standards cover activities related to umbilical cord blood, from long-term storage to distribution and transportation to support patient treatment worldwide.

Additionally, since 2013, the company has adhered to Clean Room Class 100 standards certified by the National Environmental Balancing Bureau (NEBB) from Germany. These standards ensure proper control of particles, pressure, and temperature within laboratory environments.

Following its fundraising efforts, MEDEZE plans to expand its Hair Follicle Cell Bank business by developing innovative hair follicle cell technology. This initiative aims to meet customer needs by addressing various hair and scalp-related issues, which are increasingly prevalent among the elderly. The company also intends to invest in a Robotic Cell Culture System, an advanced and internationally recognized innovation for cell storage. This technology enhances safety, minimizes human error, and reduces risks associated with environmental variables. By implementing this system, MEDEZE aims to elevate its credibility to match leading global operators, thereby attracting more customers both domestically and internationally.

Meanwhile, MEDEZE's performance for the years 2021 to 2023 recorded total revenues of 446.41 million baht, 595.70 million baht, and 701.81 million baht, respectively, with net profits of 112.06 million baht, 147.19 million baht, and 239.57 million baht, respectively.